Kreston has more than 30 years of experience with global pharmaceutical companies spanning all phases of commercialisation.
In his new role, Kreston will establish and execute global commercialization strategies and plans across the Knopp enterprise, with a particular focus on the company's lead programme, dexpramipexole, an investigational drug candidate poised to enter Phase 3 trials in hypereosinophilic syndrome and Phase 2 trials in eosinophilic asthma.
He will also be responsible for leading Knopp's corporate strategy and business development activities, and will play a key role in the company's capital strategy.
Prior to joining Knopp, Kreston was corporate VP of global marketing, inflammation and immunology at Celgene, where he led the launch of Otezla for psoriasis.
Before that, he served as worldwide VP of global marketing, immunology at Johnson and Johnson (NYSE: JNJ), where he helped engineer global expansion of the company's immunology business for Remicade and Stelara.
Earlier, at Bristol-Myers Squibb, he was worldwide VP of global marketing, immunology, responsible for launching Orencia for rheumatoid arthritis, and served as president of Consumer Medicines.
Early in his career, he was product manager for Tylenol and Pepcid at McNeil Consumer Healthcare. Kreston holds a bachelor's degree from the University of Pennsylvania and an MBA from the Cornell Johnson Graduate School of Management.
Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need.
The company's clinical-stage small molecule, dexpramipexole, is entering Phase 3 clinical studies in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma.
Knopp's preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial